9 names are moving together; 56% are participating in the current session.
Observed intraday paths are not available for this group yet.
| TICKER | Company | Sector | Today | Observed activity |
|---|---|---|---|---|
| BDC | Belden Inc | Technology | +2.3% | Group member |
| DEC | Diversified Energy Company | Energy | -2.9% | Group member |
| WOK | WORK Medical Technology Group L | Healthcare | +2.5% | Group member |
| EQPT | EquipmentShare.com Inc | Industrials | +2.9% | Group member |
| ENHA | Enhanced Group Inc. | Consumer Defensive | -1.1% | Group member |
| DNTH | Dianthus Therapeutics, Inc. | Healthcare | +2.6% | Group member |
| ARWR | Arrowhead Pharmaceuticals, Inc. | Healthcare | -3.1% | Most structurally connected |
| CATX | Perspective Therapeutics, Inc. | Healthcare | -1.0% | Group member |
| SGHC | Super Group (SGHC) Limited | Consumer Cyclical | -2.3% | Group member |
Cohort
9 namesParticipation
56% this sessionObserved history
1 daily buildsFiling coverage
7/9 membersproduct pipeline / R&D affecting expense
“The increase in net income attributable to Arrowhead Pharmaceuticals, Inc. for the three months ended December 31, 2025 compared to the same period of 2024 was primarily due to an increase in revenue from the Sarepta Collaboration Agreement, partially offset by higher research and development expenses, associated with the expansion of the Company's pipeline and progression through clinical trial phases.”
ARWR 10-Q
credit / rates affecting interest expense
“The increase was primarily due to non-cash interest expense associated with the liability related to the sale of future royalties and the Credit Facility, partially offset by higher income from increased investment yields.”
ARWR 10-K
capital investment / capacity affecting capex
“Cash used in investing activities amounted to $201.9 million, which was primarily attributable to capital expenditures of $15.2 million and investment purchases of $774.6 million, partially offset by proceeds from maturities of investments of $587.9 million.”
ARWR 10-Q
Biotechnology and Medical Devices can stay leader-led if EQPT and the next software names fail to join while ARWR keeps moving.
No high-confidence filing-linked non-members are available for this group yet.
Historical cohort observations are not available yet.